Phio Pharmaceuticals Corp PHIO

zrrsys

phio is in good hands do not forget to set your stop loss

SmoothJB Pro

Phio Pharmaceuticals Corp (NASDAQ:PHIO) was one of the biggest winners on Friday as the stock closed up $1.44 on the day with huge volumes. I alerted it when it was trading at 75c as a potential big mover due to its huge cash position and catalyst and it did not disappoint us. Looking at the technical daily chart the near-term outlook is very positive, with...

Rykin_Capital Pro+

Goals 0.71, 0.63. Invalidation at 1.02 . We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that...

KozakHlib Premium

Pupm&Dump trading strategy idea. $PHIO is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,34; stop-loss — $2,50; take-profit — $2,02/MOC Do not view this idea as a recommendation for trading or investing. It is...

SPIRITUAL7INTERELLECTUAL

will pump very fast

freddiegbruh

PHIO is very compressed

KozakHlib Premium

Pupm&Dump trading strategy idea. $PHIO is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,75; stop-loss — $3,19; take-profit — $2,31; Do not view this idea as a recommendation for trading or...

FibonacciTrader

Phio Long Trade Idea

JulianMalone

PHIO - keep in mind of the event going into the week

PennyStock101 Premium

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.